A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Non-Japanese and Japanese Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Non-Japanese and Japanese Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs MLN 3126 (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 12 Mar 2016 Results of this and other trial (see profile 257229) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 09 Apr 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 09 Mar 2015 Status changed from active, no longer recruiting to suspended, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top